4 Maguire Road
Lexington, MA 02421
United States
617-503-6500
http://www.curis.com
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 31
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. James E. Dentzer | Pres, CEO, Sec. & Director | 791.02k | N/A | 1967 |
| Dr. Robert E. Martell | Head of R&D | 470.75k | N/A | 1963 |
| Mr. William Steinkrauss | Chief Financial Officer | N/A | N/A | 1986 |
| Mr. Mark W. Noel | VP of Technology Management & Intellectual Property | N/A | N/A | 1959 |
| Dr. Reinhard Wilhelm von Roemeling | Sr. VP of Clinical Devel. | N/A | N/A | N/A |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Curis, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.